End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.5 CNY | +0.07% | -2.73% | -7.89% |
May. 16 | Bank of China Executive Vice President Steps Down | MT |
May. 02 | ICBC, CCB Name Deputy Party Secretaries | MT |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 63% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.14 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.89% | 6.48B | C | ||
-2.00% | 90.27B | A- | ||
-1.18% | 40.12B | A- | ||
-15.83% | 31.75B | B- | ||
+62.86% | 26.6B | A | ||
-21.68% | 14.41B | C | ||
-8.73% | 12.92B | B- | ||
-15.05% | 11.44B | D+ | ||
-45.69% | 11.3B | B | ||
+4.94% | 8.87B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600161 Stock
- Ratings Beijing Tiantan Biological Products Co., Ltd.